Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.
Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who were treated with revumenib, with no new safety signals found.
While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.
Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment ...
Artivion (NYSE:AORT) this week announced it received FDA humanitarian device exemption (HDE) for its AMDS Hybrid Prosthesis.
Chronic exposure to irritants, allergens, and repetitive hand washing are established risk factors for chronic hand eczema.
With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...
Casirivimab and imdevimab in combination is safe among pediatric outpatients with at least 1 risk factor for severe COVID-19.
Southlake Regional Health Centre’s Dr. Kevin Teoh is a leading cardiac surgeon. He implanted the first Perceval valve in ...
Across 62 treated patients, the combination of up to 120 mg of palazestrant with the approved dose for metastatic disease of 600 mg of ribociclib daily was well tolerated with no new safety signals or ...
MANNHEIM, Germany I December 09, 2024 I Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to ...
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets ...